Abstract
We are very pleased and proud to be able to publish this special issue of Current Cancer Drug Targets devoted to oncolytic virus therapy covering basic and clinical research on adenovirus, vaccinia virus, herpes virus, and Newcastle disease virus. In these papers, we welcome the worlds top authorities in the field who have generously contributed their latest review articles for exclusive publication in this special issue. Moreover, this issue also includes a range of opinion from government drug organizations. Here we simply wish to bring together the newest knowledge and experience in the field of cutting-edge oncolytic virus therapy for researchers and every kind of cancer therapist. The Foreword presents a historical perspective on the development of oncolytic virus together with the encouraging results of recent clinical trials (e.g., H101 has been tested in clinical trial of nearly 250 patients and approved for human use by the Chinese FDA, while PV701 has been tried in over 110 patients, as described in our special issue).
Keywords: Oncolytic virus, gene therapy, adenovirus, vaccinia virus, herpes virus, Newcastle disease virus, HF10
Current Cancer Drug Targets
Title: Oncolytic Virus Therapy - Foreword
Volume: 7 Issue: 2
Author(s): H. Kasuya, S. Takeda, S. Shimoyama, T. Shikano, N. Nomura, N. Kanazumi, S. Nomoto, H. Sugimoto and A. Nakao
Affiliation:
Keywords: Oncolytic virus, gene therapy, adenovirus, vaccinia virus, herpes virus, Newcastle disease virus, HF10
Abstract: We are very pleased and proud to be able to publish this special issue of Current Cancer Drug Targets devoted to oncolytic virus therapy covering basic and clinical research on adenovirus, vaccinia virus, herpes virus, and Newcastle disease virus. In these papers, we welcome the worlds top authorities in the field who have generously contributed their latest review articles for exclusive publication in this special issue. Moreover, this issue also includes a range of opinion from government drug organizations. Here we simply wish to bring together the newest knowledge and experience in the field of cutting-edge oncolytic virus therapy for researchers and every kind of cancer therapist. The Foreword presents a historical perspective on the development of oncolytic virus together with the encouraging results of recent clinical trials (e.g., H101 has been tested in clinical trial of nearly 250 patients and approved for human use by the Chinese FDA, while PV701 has been tried in over 110 patients, as described in our special issue).
Export Options
About this article
Cite this article as:
Kasuya H., Takeda S., Shimoyama S., Shikano T., Nomura N., Kanazumi N., Nomoto S., Sugimoto H. and Nakao A., Oncolytic Virus Therapy - Foreword, Current Cancer Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/156800907780058826
DOI https://dx.doi.org/10.2174/156800907780058826 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
subject Index To Volume 2
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Schiff Bases and Complexes: A Review on Anti-Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Increased Neuronal Injury in Clock Gene Per-1 Deficient-Mice after Cerebral Ischemia
Current Neurovascular Research Macrophages in Immunopathology of Atherosclerosis: A Target for Diagnostics and Therapy
Current Pharmaceutical Design New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Algae Polysaccharides’ Chemical Characterization and their Role in the Inflammatory Process
Current Medicinal Chemistry Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry Lipidomic Analysis of Glioblastoma Multiforme Using Mass Spectrometry
Current Metabolomics Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology EDITORIAL [Hot topic: New Therapeutic Advances and Perspectives in Tumour Angiogenesis (Guest Editor: Eddy Pasquier)]
Current Cancer Drug Targets Local Gene Delivery for Cancer Therapy
Current Gene Therapy